CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
Rhea-AI Summary
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced it will release its Q2 2025 financial results and company update after market close on Tuesday, August 5, 2025, followed by a conference call at 4:30 p.m. Eastern Time.
The company, focused on specialty pharmaceuticals, maintains a portfolio of six FDA-approved products targeting hospital acute care, gastroenterology, and oncology segments. Additionally, Cumberland has ongoing Phase II clinical programs evaluating ifetroban for three conditions: Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, CPIX declined 1.43%, reflecting a mild negative market reaction. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $747K from the company's valuation, bringing the market cap to $51M at that time.
Data tracked by StockTitan Argus on the day of publication.
A conference call will be held on August 5 at 4:30 p.m. Eastern Time to discuss the results and update.
The link to register is: https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/zpxz72fn.
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-q2-2025-financial-results--company-update-302516454.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release Q2 2025 earnings?
How can investors access Cumberland Pharmaceuticals' Q2 2025 earnings call?
What FDA-approved products does Cumberland Pharmaceuticals (CPIX) currently have?
What clinical trials is Cumberland Pharmaceuticals currently conducting?
